MovDisordV3, Main, Curation, bibRecord, 004706

Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study

Identifieur interne : 004706 ( Main/Curation ); précédent : 004705; suivant : 004707

Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study

Auteurs : Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande]

Source :

Movement Disorders [ 0885-3185 ] ; 2001-07.

RBID : ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4

Descripteurs français

Pascal (Inist)
- Encéphale, Evolution, Fluorodopa(18F), Homme, Parkinson maladie, Positon, Tomoscintigraphie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Aged, Brain (vertebrata), Caudate Nucleus (radionuclide imaging), Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Disease Progression, Emission tomography, Evolution, Female, Fluorodopa(18F), Follow-Up Studies, Human, Humans, Male, Middle Aged, PET, Parkinson Disease (radionuclide imaging), Parkinson disease, Parkinson's disease, Positron, Putamen (radionuclide imaging), Tomography, Emission-Computed, fluorodopa, positron emission tomography, progression.
MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , diagnostic use : Dihydroxyphenylalanine.
- radionuclide imaging : Caudate Nucleus, Parkinson Disease, Putamen.
- Adult, Aged, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Tomography, Emission-Computed.

Abstract

The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[18F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5‐year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean kiocc (× 10−3 min−1) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The kiocc value for the caudate nucleus was 7.5 ± 2.1 (× 10−3 min−1; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected. © 2001 Movement Disorder Society.

Url:

https://api.istex.fr/document/CD92A9CF64114C39DC4DA24600A15F13E81FF7E4/fulltext/pdf

DOI: 10.1002/mds.1139

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000248
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000248
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002F33
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006B88
to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002952
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000369
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002918
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006E17
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003D16
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003D16
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003C59
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000535
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000535
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000535
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006961

Links to Exploration step

ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study</title>
<author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name>
</author>
<author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name>
</author>
<author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name>
</author>
<author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name>
</author>
<author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name>
</author>
<author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name>
</author>
<author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1002/mds.1139</idno>
<idno type="url">https://api.istex.fr/document/CD92A9CF64114C39DC4DA24600A15F13E81FF7E4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000248</idno>
<idno type="wicri:Area/Istex/Curation">000248</idno>
<idno type="wicri:Area/Istex/Checkpoint">002F33</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Nurmi E:rate:of:progression</idno>
<idno type="wicri:Area/Main/Merge">006B88</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:01-0430453</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002952</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000369</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002918</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Nurmi E:rate:of:progression</idno>
<idno type="wicri:Area/Main/Merge">006E17</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11481683</idno>
<idno type="wicri:Area/PubMed/Corpus">003D16</idno>
<idno type="wicri:Area/PubMed/Curation">003D16</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003C59</idno>
<idno type="wicri:Area/Ncbi/Merge">000535</idno>
<idno type="wicri:Area/Ncbi/Curation">000535</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000535</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Nurmi E:rate:of:progression</idno>
<idno type="wicri:Area/Main/Merge">006961</idno>
<idno type="wicri:Area/Main/Curation">004706</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study</title>
<author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name>
<affiliation wicri:level="3"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name>
<affiliation wicri:level="3"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name>
<affiliation wicri:level="3"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Radiology, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2001-07">2001-07</date>
<biblScope unit="vol">16</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="608">608</biblScope>
<biblScope unit="page" to="615">615</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CD92A9CF64114C39DC4DA24600A15F13E81FF7E4</idno>
<idno type="DOI">10.1002/mds.1139</idno>
<idno type="ArticleID">MDS1139</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Brain (vertebrata)</term>
<term>Caudate Nucleus (radionuclide imaging)</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (diagnostic use)</term>
<term>Disease Progression</term>
<term>Emission tomography</term>
<term>Evolution</term>
<term>Female</term>
<term>Fluorodopa(18F)</term>
<term>Follow-Up Studies</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>PET</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Positron</term>
<term>Putamen (radionuclide imaging)</term>
<term>Tomography, Emission-Computed</term>
<term>fluorodopa</term>
<term>positron emission tomography</term>
<term>progression</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Caudate Nucleus</term>
<term>Parkinson Disease</term>
<term>Putamen</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Encéphale</term>
<term>Evolution</term>
<term>Fluorodopa(18F)</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Positon</term>
<term>Tomoscintigraphie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[18F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5‐year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean kiocc (× 10−3 min−1) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The kiocc value for the caudate nucleus was 7.5 ± 2.1 (× 10−3 min−1; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
<double idat="0885-3185:2001:Nurmi E:rate:of:progression"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rate of progression in Parkinson's disease: A 6-[<sup>18</sup>
F]fluoro-L-dopa PET study</title>
<author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, and Turku PET Centre, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, and Turku PET Centre, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Radiochemistry, Laboratory, Turku PET Centre</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Radiochemistry, Laboratory, Turku PET Centre</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Radiochemistry, Laboratory, Turku PET Centre</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Radiology, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, and Turku PET Centre, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0430453</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0430453 INIST</idno>
<idno type="RBID">Pascal:01-0430453</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002952</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000369</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002918</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Nurmi E:rate:of:progression</idno>
<idno type="wicri:Area/Main/Merge">006E17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rate of progression in Parkinson's disease: A 6-[<sup>18</sup>
F]fluoro-L-dopa PET study</title>
<author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, and Turku PET Centre, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, and Turku PET Centre, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Radiochemistry, Laboratory, Turku PET Centre</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Radiochemistry, Laboratory, Turku PET Centre</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Radiochemistry, Laboratory, Turku PET Centre</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Radiology, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, and Turku PET Centre, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain (vertebrata)</term>
<term>Emission tomography</term>
<term>Evolution</term>
<term>Fluorodopa(18F)</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Positron</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Fluorodopa(18F)</term>
<term>Encéphale</term>
<term>Evolution</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6-[<sup>18</sup>
F]fluoro-L-dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5-year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean k<sub>i</sub>
<sup>occ</sup>
 (x 10<sup>-3</sup>
 min<sup>-1</sup>
) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The k<sub>i</sub>
<sup>occ</sup>
 value for the caudate nucleus was 7.5 ± 2.1 (× 10<sup>-3</sup>
 min<sup>-1</sup>
; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P <0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study</title>
<author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name>
</author>
<author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name>
</author>
<author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name>
</author>
<author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name>
</author>
<author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name>
</author>
<author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name>
</author>
<author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1002/mds.1139</idno>
<idno type="url">https://api.istex.fr/document/CD92A9CF64114C39DC4DA24600A15F13E81FF7E4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000248</idno>
<idno type="wicri:Area/Istex/Curation">000248</idno>
<idno type="wicri:Area/Istex/Checkpoint">002F33</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Nurmi E:rate:of:progression</idno>
<idno type="wicri:Area/Main/Merge">006B88</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study</title>
<author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name>
<affiliation wicri:level="3"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name>
<affiliation wicri:level="3"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name>
<affiliation wicri:level="3"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Radiology, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name>
<affiliation wicri:level="4"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2001-07">2001-07</date>
<biblScope unit="vol">16</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="608">608</biblScope>
<biblScope unit="page" to="615">615</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CD92A9CF64114C39DC4DA24600A15F13E81FF7E4</idno>
<idno type="DOI">10.1002/mds.1139</idno>
<idno type="ArticleID">MDS1139</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PET</term>
<term>Parkinson's disease</term>
<term>fluorodopa</term>
<term>positron emission tomography</term>
<term>progression</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[18F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5‐year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean kiocc (× 10−3 min−1) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The kiocc value for the caudate nucleus was 7.5 ± 2.1 (× 10−3 min−1; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.</title>
<author><name sortKey="Nurmi, E" sort="Nurmi, E" uniqKey="Nurmi E" first="E" last="Nurmi">E. Nurmi</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, and Turku PET Centre, University of Turku, Turku, Finland.</nlm:affiliation>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Ruottinen, H M" sort="Ruottinen, H M" uniqKey="Ruottinen H" first="H M" last="Ruottinen">H M Ruottinen</name>
</author>
<author><name sortKey="Bergman, J" sort="Bergman, J" uniqKey="Bergman J" first="J" last="Bergman">J. Bergman</name>
</author>
<author><name sortKey="Haaparanta, M" sort="Haaparanta, M" uniqKey="Haaparanta M" first="M" last="Haaparanta">M. Haaparanta</name>
</author>
<author><name sortKey="Solin, O" sort="Solin, O" uniqKey="Solin O" first="O" last="Solin">O. Solin</name>
</author>
<author><name sortKey="Sonninen, P" sort="Sonninen, P" uniqKey="Sonninen P" first="P" last="Sonninen">P. Sonninen</name>
</author>
<author><name sortKey="Rinne, J O" sort="Rinne, J O" uniqKey="Rinne J" first="J O" last="Rinne">J O Rinne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11481683</idno>
<idno type="pmid">11481683</idno>
<idno type="wicri:Area/PubMed/Corpus">003D16</idno>
<idno type="wicri:Area/PubMed/Curation">003D16</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003C59</idno>
<idno type="wicri:Area/Ncbi/Merge">000535</idno>
<idno type="wicri:Area/Ncbi/Curation">000535</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000535</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Nurmi E:rate:of:progression</idno>
<idno type="wicri:Area/Main/Merge">006961</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.</title>
<author><name sortKey="Nurmi, E" sort="Nurmi, E" uniqKey="Nurmi E" first="E" last="Nurmi">E. Nurmi</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, and Turku PET Centre, University of Turku, Turku, Finland.</nlm:affiliation>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea>
<placeName><settlement type="city">Turku</settlement>
<region type="région" nuts="2">Finlande occidentale</region>
</placeName>
<orgName type="university">Université de Turku</orgName>
</affiliation>
</author>
<author><name sortKey="Ruottinen, H M" sort="Ruottinen, H M" uniqKey="Ruottinen H" first="H M" last="Ruottinen">H M Ruottinen</name>
</author>
<author><name sortKey="Bergman, J" sort="Bergman, J" uniqKey="Bergman J" first="J" last="Bergman">J. Bergman</name>
</author>
<author><name sortKey="Haaparanta, M" sort="Haaparanta, M" uniqKey="Haaparanta M" first="M" last="Haaparanta">M. Haaparanta</name>
</author>
<author><name sortKey="Solin, O" sort="Solin, O" uniqKey="Solin O" first="O" last="Solin">O. Solin</name>
</author>
<author><name sortKey="Sonninen, P" sort="Sonninen, P" uniqKey="Sonninen P" first="P" last="Sonninen">P. Sonninen</name>
</author>
<author><name sortKey="Rinne, J O" sort="Rinne, J O" uniqKey="Rinne J" first="J O" last="Rinne">J O Rinne</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Caudate Nucleus (radionuclide imaging)</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (diagnostic use)</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Putamen (radionuclide imaging)</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Caudate Nucleus</term>
<term>Parkinson Disease</term>
<term>Putamen</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Tomography, Emission-Computed</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6-[(18)F]fluoro-L-dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5-year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean k(i)(occ) (x 10(-3) min(-1)) in the anterior putamen was 5.6 +/- 2.7 (mean +/- S.D.; 55% of the control mean) and in the posterior putamen 4.5 +/- 2.4 (45% of the control mean). The k(i)(occ) value for the caudate nucleus was 7.5 +/- 2.1 (x 10(-3) min(-1); 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 +/- 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 +/- 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 +/- 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004706 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004706 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4
   |texte=   Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study

Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri